Want to see BRTX full AI Analyst Report?
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
Select Model
Select Model
Rating:39Underperform
Price Target:
$2.00
▲(809.09% Upside)
Action:Reiterated
Date:10/10/26
BRTX scores low primarily due to very weak financial performance (tiny and declining revenue, extreme losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation offers limited support because the company is unprofitable (negative P/E) and there is no dividend yield provided, while corporate events add additional uncertainty via filing/compliance risk, product shipment suspension, and leadership/legal disputes.
Positive Factors
Minimal leverage
Effectively no debt reduces interest burden and financial risk, preserving flexibility while the company funds clinical development. This gives management more room to allocate limited capital toward research and operations without servicing a substantial debt load.
Negative Factors
Tiny, declining revenue
Very small and sharply declining revenue provides little support for the current operating structure and leaves the company far from self-sustaining commercialization. Continued weakness would make it harder to fund clinical programs internally or demonstrate durable market adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal leverage
Effectively no debt reduces interest burden and financial risk, preserving flexibility while the company funds clinical development. This gives management more room to allocate limited capital toward research and operations without servicing a substantial debt load.
Read all positive factors
BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.64M
Dividend YieldN/A
Average Volume (3M)38.27K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-8.47%
EPS Growth25.62%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-22.20
Shares Outstanding1,381,128
10 Day Avg. Volume46,534
30 Day Avg. Volume38,272
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue3.54
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-6.6
Revenue Forecast (FY)$2.50M
BioRestorative Therapies Business Overview & Revenue Model
Company Description
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic ...
How the Company Makes Money
Because BioRestorative Therapies is a clinical-stage biotech, its revenue model is primarily centered on funding and deal-driven monetization rather than recurring sales of marketed products. Specifically: (1) Equity financing: The company has his...
BioRestorative Therapies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.Positive Updates
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Negative Updates
Significant Revenue Decline
Third-quarter 2025 revenues were $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to the timing of orders for the developing biocosmeceutical revenue stream.
Read all updates
Q3-2025 Updates
Positive
Negative
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Read all positive updates
Company Guidance
In the third quarter of 2025, BioRestorative Therapies reported a mixed financial performance, with revenues significantly declining to approximately $11,800 from $233,600 in the same period of 2024, primarily due to timing in the biocosmeceutical revenue stream. The company reported a loss from operations of $3.7 million, up from $2.3 million in the previous year, and a net loss of $3 million or $0.33 per share, compared to a net loss of $1 million or $0.13 per share in 2024. Despite these financial challenges, BioRestorative Therapies ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities, excluding $1.1 million from recent financing. On the clinical front, the company is advancing its Phase II BRTX-100 study for chronic lumbar disc disease, with enrollment nearing completion and a potential Type B FDA meeting anticipated. The company also highlighted substantial progress in its ThermoStem program targeting obesity, while continuing discussions for a potential licensing agreement. The biocosmeceuticals business shows promise, with strategic leadership changes and a focus on expanding distribution channels, although revenue guidance remains uncertain.BioRestorative Therapies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 357.87K | 359.70K | 401.00K | 145.80K | 119.80K | 46.00K |
| Gross Profit | 329.55K | 335.86K | 372.93K | 145.80K | 119.80K | 46.00K |
| EBITDA | -10.85M | -14.03M | -8.79M | -14.97M | -13.10M | -42.40M |
| Net Income | -11.06M | -14.24M | -8.98M | -10.42M | -13.22M | -44.30M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 2.95M | 10.73M | 11.07M | 14.75M | 21.03M |
| Total Debt | 34.52K | 0.00 | 0.00 | 162.32K | 301.64K | 670.70K |
| Total Liabilities | 1.61M | 3.72M | 3.75M | 2.61M | 6.14M | 856.50K |
| Stockholders Equity | 3.03M | 356.74K | 8.53M | 10.00M | 10.29M | 21.60M |
Cash Flow | ||||||
| Free Cash Flow | -11.90M | -10.91M | -8.34M | -6.60M | -6.35M | -3.36M |
| Operating Cash Flow | -11.82M | -10.79M | -8.23M | -6.43M | -5.91M | -3.33M |
| Investing Cash Flow | 7.50M | 8.90M | 514.53K | 3.25M | -13.40M | -30.66K |
| Financing Cash Flow | 6.20M | 2.85M | 7.38M | 2.35M | 0.00 | 21.32M |
BioRestorative Therapies Technical Analysis
Negative
0.22
Price Trends
3.32
Negative
5.12
Negative
7.93
Negative
Market Momentum
-0.40
Negative
22.99
Positive
25.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 2.40, below the 50-day MA of 3.32, and below the 200-day MA of 7.93, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 22.99 is Positive, neither overbought nor oversold. The STOCH value of 25.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.
BioRestorative Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $13.71M | -0.32 | -165.71% | ― | ― | 77.68% | |
47 Neutral | $20.61M | -1.34 | -207.47% | ― | ― | 38.55% | |
47 Neutral | $13.77M | -0.07 | 204.18% | ― | ― | 35.03% | |
43 Neutral | $16.20M | -2.02 | -56.96% | ― | -56.64% | 64.88% | |
39 Underperform | $2.64M | -0.09 | -423.84% | ― | -8.47% | 25.62% |
* Healthcare Sector Average
BRTX
BioRestorative Therapies
1.91
-30.09
-94.03%
CLRB
Cellectar Biosciences
1.45
-3.44
-70.35%
MRKR
Marker Therapeutics
0.97
-0.05
-4.80%
COCP
Cocrystal Pharma
1.07
0.01
0.94%
AEON
AEON Biopharma
0.28
-0.79
-74.21%
BioRestorative Therapies Corporate Events
Business Operations and StrategyExecutive/Board Changes
BioRestorative Therapies Strengthens Board With New Director
Positive
Oct 9, 2026
On October 7, 2026, BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director to fill the vacancy created by the resignation of director Katharyn Field effective August 31, 2026. Currie, who will serve until the 2027 annual m...
Executive/Board ChangesLegal ProceedingsRegulatory Filings and Compliance
BioRestorative Therapies Faces Disputed Executive Resignation Claim
Negative
Sep 11, 2026
On September 4, 2026, BioRestorative Therapies received the immediate resignation of Mr. Silva from his role as Vice President of Research and Development and all other officer positions. Silva claims his resignation is for “Good Reason̶...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
BioRestorative Therapies Announces 1-for-20 Reverse Stock Split
Neutral
Sep 2, 2026
On September 2, 2026, BioRestorative Therapies’ board approved a 1-for-20 reverse split of its common stock, and the company filed a Certificate of Change in Nevada to implement it. The action, which did not require shareholder approval unde...
Business Operations and StrategyExecutive/Board Changes
BioRestorative Therapies Announces Leadership and Governance Restructuring
Neutral
Sep 2, 2026
BioRestorative Therapies announced a series of leadership changes executed between August 26 and September 1, 2026, reshaping its executive team and board governance. The restructuring relies on consulting agreements with external firms, signaling...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BioRestorative Therapies Faces Nasdaq Delinquency Notice Risk
Negative
Aug 25, 2026
On August 21, 2026, BioRestorative Therapies received a delinquency notification from Nasdaq after failing to timely file its Form 10-Q for the quarter ended June 30, 2026, putting it out of compliance with listing rules requiring current financia...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BioRestorative Therapies Halts ExoCR and BioX Shipments
Negative
Aug 14, 2026
On August 7, 2026, BioRestorative Therapies, Inc. suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines, effective immediately, while it undertakes a business review and regulatory assessment. The company is exami...
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsRegulatory Filings and Compliance
BioRestorative Therapies Overhauls Leadership and Board Governance
Negative
Jul 17, 2026
On July 8, 2026, BioRestorative Therapies amended executive employment agreements for its then chief executive, chief financial officer and vice president of research and development, narrowing severance and equity-vesting benefits to apply only i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.